Deadline: 30-Jan-2025
Pfizer is pleased to announce the Health Services Research Grant to Improve Management of mBC Patients Treated with Tucatinib.
The intent of this RFP is to support Investigator Sponsored/General Research projects that will implement and assess the impact of therapy management approaches for patients with HER2+ Metastatic Breast Cancer (mBC) receiving tucatinib in combination with trastuzumab and capecitabine.
Funding Information
- Individual projects requesting up to $250,000 will be considered.
Project Length
- 18-month suggested project length (may be shorter or longer).
Project Types and Area of Interest
- Organizations are invited to submit proposals for initiatives that will implement innovative and community-accessible approaches to improving therapy management with the 3-drug regimen of tucatinib, trastuzumab and capecitabine, including increasing patients’ understanding, quality of life, or adherence to treatment and/or facilitate follow-up or symptom management in daily clinical practice.
- Projects should be aimed at improving patient care and outcomes using a research framework or “Health Services Research” type approach to evaluate and assess the impact of the interventions.
Eligibility Criteria
- Geographic Scope
- Global
- Applicant Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a terminal degree in Pharmacy, Social Work, or other relevant discipline.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
For more information, visit Pfizer.